DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY

DNA-launched Nipah virus vaccines and therapeutics

Project disclaimer

Disclaimer: The data for this page has been produced from IATI data published by DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY. Please contact them (Show Email Address) if you have any questions about their data.

Description

Background: Despite the significant threat Nipah virus poses to both human and animal populations across Southeast Asia, neither vaccines nor therapeutics are currently available to prevent or treat infection. If the delivery challenge could be overcome, DNA-launched approaches have advantages over other platforms (including mRNA) for vaccines and therapeutics, such as low production cost, time-to-impact, and enhanced stability for transportation/storage. We have generated an injectable DNA vaccine platform which we are exemplifying as a Zika vaccine (IUK, SBRI funding), which is currently being tested in mouse and non-human primate models. Translating the gains of the effective delivery system with DNA-encoded antigens or therapeutics would be transformative for tackling Nipah virus. Study aims: We propose to exploit our recently established DNA-delivery platform to advance the development of effective, affordable, and scalable Nipah virus vaccines and therapeutics. Our platform is based on polymer/peptide nanoformulations that are vectors for DNA delivery. Due to the simplicity of formulation this opens up the possibility of a tractable and deployable method to vaccinate and treat Nipah in a ‘One Health’ approach tackling both human and animal disease. This study aims to generate the pre-clinical efficacy data needed to support the further translation of the approach. The approach: Whilst the protective antigens from the Nipah virus are well defined and could be readily engineered into the DNA vaccine platform, there are a limited number of human monoclonal antibody (mAb)-based therapeutic candidates, with only one in clinical testing. We therefore propose to isolate new therapeutic candidate mAbs from human volunteers in Malaysia, who previously recovered from Nipah virus infection. Both DNA-encoded vaccine and therapeutic mAb candidates will be evaluated in preclinical animal models. After initial optimisation using a mouse model, vaccine and therapeutic candidates will be assessed evaluated for immunogenicity and pharmacokinetics, respectively, in pigs. And their efficacy to protect against Nipah virus infection will be tested in hamsters. We will also compare plasmid and synthetic DNA systems (dbDNA) which will improve low and single-dose efficacy, with more rapid and deployable manufacture. Outputs: The major gain here is the discovery and preclinical testing of DNA encoded Nipah virus vaccine and therapeutic candidates, supporting their further clinical development. Furthermore, the livestock testing of the platform could be transformative as a route as an agricultural vaccine, which could prevent and contain Nipah virus outbreaks in affected areas of Southeast Asia

Objectives

Background: Despite the significant threat Nipah virus poses to both human and animal populations across Southeast Asia, neither vaccines nor therapeutics are currently available to prevent or treat infection. If the delivery challenge could be overcome, DNA-launched approaches have advantages over other platforms (including mRNA) for vaccines and therapeutics, such as low production cost, time-to-impact, and enhanced stability for transportation/storage. We have generated an injectable DNA vaccine platform which we are exemplifying as a Zika vaccine (IUK, SBRI funding), which is currently being tested in mouse and non-human primate models. Translating the gains of the effective delivery system with DNA-encoded antigens or therapeutics would be transformative for tackling Nipah virus. Study aims: We propose to exploit our recently established DNA-delivery platform to advance the development of effective, affordable, and scalable Nipah virus vaccines and therapeutics. Our platform is based on polymer/peptide nanoformulations that are vectors for DNA delivery. Due to the simplicity of formulation this opens up the possibility of a tractable and deployable method to vaccinate and treat Nipah in a ‘One Health’ approach tackling both human and animal disease. This study aims to generate the pre-clinical efficacy data needed to support the further translation of the approach. The approach: Whilst the protective antigens from the Nipah virus are well defined and could be readily engineered into the DNA vaccine platform, there are a limited number of human monoclonal antibody (mAb)-based therapeutic candidates, with only one in clinical testing. We therefore propose to isolate new therapeutic candidate mAbs from human volunteers in Malaysia, who previously recovered from Nipah virus infection. Both DNA-encoded vaccine and therapeutic mAb candidates will be evaluated in preclinical animal models. After initial optimisation using a mouse model, vaccine and therapeutic candidates will be assessed evaluated for immunogenicity and pharmacokinetics, respectively, in pigs. And their efficacy to protect against Nipah virus infection will be tested in hamsters. We will also compare plasmid and synthetic DNA systems (dbDNA) which will improve low and single-dose efficacy, with more rapid and deployable manufacture. Outputs: The major gain here is the discovery and preclinical testing of DNA encoded Nipah virus vaccine and therapeutic candidates, supporting their further clinical development. Furthermore, the livestock testing of the platform could be transformative as a route as an agricultural vaccine, which could prevent and contain Nipah virus outbreaks in affected areas of Southeast Asia

---

Location

The country, countries or regions that benefit from this Programme.

Malaysia

Disclaimer: Country borders do not necessarily reflect the UK Government's official position.